TRIB
Trinity Biotech plc
NASDAQ · Healthcare · Medical - Diagnostics & Research · IE
$9.41
−1.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 43.9M | 43.8M | 61.6M | 56.8M | 62.5M |
| Cost of Revenue | 28.3M | 26.9M | 40.1M | 37.4M | 52.7M |
| Gross Profit | 15.5M | 16.9M | 21.4M | 19.4M | 22.0M |
| Operating Expenses | |||||
| R&D Expense | 3.6M | 3.6M | 4.5M | 4.4M | 4.1M |
| SG&A Expense | 23.2M | 24.7M | 28.8M | 31.2M | 29.2M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 9.2M | 11.0M | (343.0K) |
| Total Operating Expenses | 26.8M | 28.3M | 42.6M | 46.5M | 33.0M |
| Cost and Expenses | 55.1M | 55.2M | 82.7M | 83.9M | 81.9M |
| Operating Income (EBIT) | (11.3M) | (11.4M) | (21.2M) | (27.0M) | (15.3M) |
| Non-Operating | |||||
| Interest Income | 997.23 | 221.0K | — | 1.2M | 303.0K |
| Interest Expense | 21.4M | 13.1M | 9.6M | 10.1M | 24.7M |
| Net Interest Income | (21.4M) | (12.9M) | (9.6M) | (9.0M) | (24.4M) |
| Other Non-Op Income/Expense | (26.0M) | (25.8M) | (9.6M) | (9.9M) | (24.4M) |
| Non-Operating Income (excl Interest) | — | 12.6M | (2.4M) | (1.2M) | 3.8M |
| EBT (Pre-Tax Income) | (37.2M) | (37.2M) | (30.7M) | (36.9M) | (43.8M) |
| Income Tax Expense | 202.7K | 199.0K | 486.0K | (59.0K) | (194.0K) |
| Bottom Line | |||||
| Net Income | (37.4M) | (37.4M) | (31.8M) | (24.0M) | (41.0M) |
| Earnings from Cont. Ops | (37.4M) | (37.4M) | (31.2M) | (36.9M) | (43.6M) |
| Earnings from Discont. Ops | — | — | (573.0K) | 12.8M | 2.6M |
| Bottom Line Net Income | (37.4M) | (37.4M) | (31.8M) | (24.0M) | (41.0M) |
| Per Share | |||||
| Basic EPS | ($60.60) | ($60.00) | ($52.98) | ($96.00) | ($180.00) |
| Diluted EPS | ($60.60) | ($60.00) | ($52.98) | ($96.00) | ($156.00) |
| Revenue Per Share | $70.64 | $70.71 | $102.82 | $222.73 | $278.00 |
| Shares | |||||
| Basic Shares Outstanding | 620920 | 619189 | 598654 | 255165 | 224898 |
| Diluted Shares Outstanding | 620920 | 619189 | 598654 | 255165 | 259164 |
| Profitability Metrics | |||||
| EBITDA | (8.6M) | (21.4M) | (16.9M) | (24.1M) | (16.7M) |
| D&A | 2.7M | 2.7M | 1.9M | 1.8M | 2.3M |
| EBIT | (11.3M) | (24.1M) | (18.8M) | (25.9M) | (19.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025